Larad's Virotrac Technology uses viral proteins that self-assemble to form virus-like particles (VLPs), which keep pace with viral pathogens as they evolve when used in vaccines. Larad's first VLPs, developed for Infectious Bursal Disease Virus, use capsid proteins pVP2 and VP3.
VLPs are structurally analogous to viruses and induce a strong immune response, but contain no genetic material and cannot cause disease. Platform vaccines made from VLPs can be rapidly re-engineered to keep pace with mutating field viruses, opposed to conventional vaccines that gradually become less effective.
Platform Vaccines are not Autogenous vaccines, which are given more stringent regulations by the USDA Center for Veterinary Biologics (CVB). Autogenous vaccines are required to be prepared using an isolated pathogen from the farm where the vaccine is intended to be used, and vaccine batches are only approved for use over a short time. The CVB approved Platform Vaccines for any geographic location in the US and there is no limit on the length of time they can be used (VS Memorandum #800.213).
Larad's VLP vaccines also eliminate the need to isolate and propagate the pathogens prior to vaccine production, which significantly reduces the time needed to produce a safe, custom product.
Genetic engineering (cloning and protein expression) in the baculovirus expression system is used to produce the viral proteins in Larad’s VLPs. Baculovirus does not present a health hazard for humans or animals and can be inactivated using several simple techniques, so it has little to no impact on the final product. The baculovirus system has shown to be exceptional in creating consistent, quality particles that require minimal downstream processing, reducing the cost of production and the time needed to process the materials into a final product.
Larad continues to conduct research to develop new platform technologies using virus-like particles and subunit proteins. Current work includes the development of a VLP-based vaccine delivery platform (VLP-c) designed to protect subunit vaccine antigens during production, storage, and delivery.
Larad has an exclusive worldwide license to the IBDV-VLP & IPNV-VLP technology covered under the following US Patents: 9,732,144; 10,086,062; & 10,100,101.
International patents for the same technology are pending.